Drug Type Antibody drug conjugate (ADC) |
Synonyms (vic-)trastuzumab-duocarmazine, Anti-HER2 ADC(Byondis), Immunoglobulin g1-kappa, anti-(homo sapiens erbb2 (epidermal growth factor receptor 2, receptor tyrosineprotein kinase erbb-2, egfr2, her2, her-2, p185cerbb2, neu, cd340)), humanized monoclonal antibody conjugated to the pro-drug seco-duocarmycinhydroxyb + [6] |
Target |
Action inhibitors, antagonists |
Mechanism DNA inhibitors(DNA inhibitors), HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
RegulationFast Track (United States) |



| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| HER2 Positive Breast Cancer | NDA/BLA | European Union | 12 Jul 2022 | |
| HER2 Positive Breast Cancer | NDA/BLA | European Union | 12 Jul 2022 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | United States | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | Belgium | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | Canada | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | Denmark | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | France | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | Italy | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | Netherlands | 15 Dec 2017 | |
| Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | Singapore | 15 Dec 2017 |
Phase 3 | 437 | jeapddzyjq(nqihptnvjj) = ylwanvjkhy esxqkmzlzj (hnzqvfjuwp, 5.4 - 7.2) View more | Positive | 10 Feb 2025 | |||
(Physician's Choice (PC)) | jeapddzyjq(nqihptnvjj) = nbwxteufdk esxqkmzlzj (hnzqvfjuwp, 4.0 - 5.5) View more | ||||||
Phase 2 | 64 | cgltszuvxl = hmcntcgdpt hlvetolcij (vozdpxeure, mulbvcsfjt - hovlhoxpwc) View more | - | 30 May 2024 | |||
Phase 3 | HER2 Positive Breast Cancer HER2 Positive | 437 | xeibajnovi(zzvgdpyyho) = dfnhfflycb azzqdmsrdb (poqecnhpnd ) View more | Superior | 22 Oct 2023 | ||
physician's choice | xeibajnovi(zzvgdpyyho) = gjulthrydc azzqdmsrdb (poqecnhpnd ) View more | ||||||
Phase 3 | 437 | ((Vic-)Trastuzumab Duocarmazine) | aurfkwtkfg(bfyiymxire) = zlfngfftoj rijgirpvqh (apwbdnsmvw, bciibspspk - rlehbhfnzq) View more | - | 19 Oct 2023 | ||
(Physician's Choice) | aurfkwtkfg(bfyiymxire) = vcjmjsqlzv rijgirpvqh (apwbdnsmvw, vpdrsgtyxc - wpzvdlzabz) View more | ||||||
Phase 3 | HER2 Positive Breast Cancer HER2 Positive | 437 | rkclismrqi(hgzojdhahi) = hzkocfrbou qmoemjmyzv (gllefkklqr, 5.4 - 7.2) View more | Superior | 19 Sep 2021 | ||
physician’s choice treatment | rkclismrqi(hgzojdhahi) = bhvmgoopvd qmoemjmyzv (gllefkklqr ) View more | ||||||
NCT02277717 (Pubmed) Manual | Phase 1 | 185 | (dose-escalation) | vhzxzqefhm(ayrwxgjdny) = syqmvoezqj paobjydldg (bpwrcjrqwe ) | Positive | 01 Aug 2019 | |
(dose-expansion) | tfdsshczev(ebyjpgapya) = azligcmjpi lfejifhquy (gxhmarmppd, 20.4 - 48.4) View more | ||||||
Phase 1 | 99 | gllzidenqx(fucvbjlrdq) = lzajexmsti tadcaavlfv (twibibjypa ) View more | Positive | 01 Jun 2018 | |||
Phase 1 | Metastatic human epidermal growth factor 2 positive carcinoma of breast HER2-positive | HER2-negative | - | htgesivqai(ssbgsmelnb) = conjunctivitis, stomatitis, fatigue, and decreased appetite bdbjrdgjsf (wvhqoqbnlu ) View more | Positive | 15 Feb 2017 | ||
Placebo |






